Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Renal Cell Carcinoma – Geographic Focus: China – China In-Depth – Renal Cell Carcinoma
The renal cell carcinoma (RCC) treatment landscape in China has evolved rapidly since the introduction of targeted therapies, including TKIs (Pfizer’s Sutent and Inlyta, Novartis’s Votrient,…
Renal Cell Carcinoma – Unmet Need – Unmet Need – Advanced or Metastatic Renal Cell Carcinoma (US/EU)
The treatment of advanced or metastatic renal cell carcinoma is dominated by immune checkpoint inhibitors (e.g., Merck & Co.’s Keytruda, BMS’s Opdivo and Yervoy) and small-molecule tyrosine…
Renal Cell Carcinoma – Current Treatment – Current Treatment: Physician Insights – Renal Cell Carcinoma (US)
The addition of immune checkpoint inhibitors to the renal cell carcinoma armamentarium has significantly changed the treatment of this disease. In 2021, Keytruda (Merck & Co.) became the first…
Renal Cell Carcinoma – Current Treatment – Treatment Sequencing – Renal Cell Carcinoma (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…